This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

5 Dumbest Things on Wall Street This Week: April 5

Stocks in this article: RPRX AAPL FBN DELL

5. Repros Reproach

Markets were closed last Friday in honor of Good Friday. Luckily for us, Repros Therapeutics (RPRX) CEO Joe Podolski generously provided more than enough dumbness last Thursday to tide us through the long holiday weekend.

On a conference call last Thursday morning, Podolski told analysts that his experimental testosterone drug Androxal helped gay Cubans have more sex. The gay Cubans entered the clinical trial with low testosterone, according to Podolski, yet after taking Androxal, their testosterone levels soared, leading to lots and lots and lots of sex.

Seriously, we're not joking. We may kid about a lot of things, but gay Cuban sex is not one of them.

Anyway, Podolski said the gay Cuban men had so much sex that it caused their sperm counts to drop precipitously. But he urged the crowd not to blame the plunge on Androxal. Podolski maintained instead that the lower sperm counts were the result of the gay Cubans having so much sex that their ammunition ran low.

What more can we say Dumbest fans? Res ipsa loquitur .

And if that wasn't enough, TheStreet's Adam Feuerstein reported that at another point during the conference call, Podolski disclosed that a nurse at one of the Androxal clinical trial sites fabricated baseline sperm counts for patients. When Repros discovered the data fraud, the company changed the fishy numbers and everything turned out fine.

A second phase III study of Androxal is under way with enrollment expect to wrap in May. Podolski insisted the data announced Thursday should convince investors that the second study will also be positive.

Repros bulls are probably looking forward to the next report and not just for its racy content. Shares of the stock spiked nearly 80% on Podolski's pronouncements despite the trial's inconsistencies and the missing Androxal data.

Then again, fundamentals aren't really a factor when it comes to Repros stock. Nearly half the company's shares have been sold short, opening up the possibility for the bulls to once again squeeze the bears where it hurts.

And that can't be good for their sperm counts either.

1 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs